Oncology Drug Cost Sharing Would Decline 42% Under Medicare Part D Redesign

Cost sharing reductions resulting from US Senate drug pricing legislation would vary across categories but the biggest decreases are likely for oncology drugs, antidiabetics and psychotherapeutics, a recent analysis by Manatt Health finds.